Social, Behavioral and Administrative Pharmacy Sciences: Behavior, Economics and Regulation
Behaviour, communication and systems
This domain blends health behaviour theory, communication, pharmacoepidemiology, pharmacoeconomics, regulation and management. Know the transtheoretical model stages (precontemplation, contemplation, preparation, action, maintenance); the health belief model constructs (perceived susceptibility, severity, benefits, barriers, cues to action, self-efficacy); and motivational interviewing as a collaborative, non-judgemental style that builds on the patient's own reasons for change. Adherence is a behaviour shaped by cost, regimen complexity, side effects and health literacy - not a personality trait.
Economics and epidemiology
Cost-minimization analysis compares options with equal outcomes; cost-effectiveness uses natural units such as life-years gained; cost-utility uses QALYs; cost-benefit monetizes outcomes. The incremental cost-effectiveness ratio is ICER = (Cost_new − Cost_old) / (Effect_new − Effect_old). In epidemiology, separate incidence from prevalence, relative risk from odds ratio, and remember that a case-control design cannot yield incidence. Regulatory questions test scheduling, post-market reporting, and the distinction between pre-market approval and ongoing pharmacovigilance.
Traps
Reading an ICER as an average cost per patient rather than an incremental ratio; using cost-effectiveness when outcomes differ in quality as well as quantity; conflating adherence with persistence; and assuming that a statistically significant trial result is clinically important.
Worked example
A new drug costs $40,000 more per patient and produces 2 additional QALYs. ICER = 40,000 / 2 = $20,000 per QALY, which falls below a common willingness-to-pay threshold of about $50,000 per QALY and would generally be judged cost-effective. Note that the total budget impact may still be unaffordable - budget impact and cost-effectiveness answer different questions.